chufangao/CTO huggingface dataset:
Clinical trial NCT02165345: Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
Official title: Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-07-16
Primary completion date: 2021-11-24
Completion date: 2021-11-24
Clinical trial NCT04685499: Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
Official title: Phase 2 Study of OBP-301 (Telomelysin ™) in Combination With Pembrolizumab and Stereotactic Body Irradiation in Patients With Head and Neck Squamous Cell Carcinoma With Inoperable, Recurrent or Progressive Disease
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated due to low participant enrollment.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-03
Primary completion date: 2022-03-08
Completion date: 2022-06-03
Plan to share individual participant data: NO
Clinical trial NCT04197479: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Official title: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Acronym: MAESTRO-NAFLD1
Sponsor: Madrigal Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1343.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-16
Primary completion date: 2023-01-06
Completion date: 2023-01-06
Clinical trial NCT04570384: Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19
Official title: Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness
Sponsor: Asklepion Pharmaceuticals, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-15
Primary completion date: 2021-08-30
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT05647447: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate
Official title: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (POSH-MAP)
Acronym: POSH-MAP
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Development of the drug program has been discontinued
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-03
Primary completion date: 2023-09-22
Completion date: 2023-10-05
Clinical trial NCT02506114: Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Official title: An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-10-06
Primary completion date: 2020-04-22
Completion date: 2020-04-22
Limitations and caveats: Study was terminated early due to low accrual, thus outcomes are not sufficiently powered for statistical significance.
Plan to share individual participant data: NO
Clinical trial NCT04729790: Randomized Clinical Trial of Standard FMT Treatments
Official title: Phase II Randomized Clinical Trial of Standard FMT Treatments: Non-powered Pilot Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (RCDI) Using Either Single or Three Combined Products From Healthy Donors
Acronym: FMT
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-10
Primary completion date: 2022-01-30
Completion date: 2022-04-30
Plan to share individual participant data: NO
Clinical trial NCT02654132: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Official title: An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 117.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-18
Primary completion date: 2018-01-17
Completion date: 2021-10-21
Baseline population: All randomized participants
Clinical trial NCT04338906: Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
Official title: Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection
Acronym: CLOCC
Sponsor: Heinrich-Heine University, Duesseldorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not being standard of care anymore as time evolved.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: YES
IPD time frame: 3 Months after publication
IPD access criteria: Open
Clinical trial NCT03043430: Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
Official title: Anxiolysis for Emergency Department Procedures in Pediatric Patients Using Intranasal Ketamine Compared With Intranasal Midazolam: A Randomized Controlled Trial
Sponsor: Brooke Army Medical Center (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Research manpower shortage
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-31
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
Clinical trial NCT01982175: Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Official title: A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia
Acronym: CLL004
Sponsor: Shanghai Zhangjiang Biotechnology Limited Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: recruiting difficulties
Enrollment: 120.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2011-07-31
Primary completion date: 2021-02-28
Completion date: 2022-06-30
Clinical trial NCT04028388: ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Official title: A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
Sponsor: Modra Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 135.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-17
Primary completion date: 2021-11-29
Completion date: 2021-11-29
Baseline population: Baseline characteristics have been provided for the Full Analysis Set (FAS). All patients who received at least 1 dose of intravenous docetaxel (Cohort 1) or 1 full cycle of ModraDoc006/r (Cohort 2) and had at least 1 post-baseline tumor assessment were included in the FAS.
Plan to share individual participant data: NO
Clinical trial NCT05496894: A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Official title: A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to the company's project adjustment, decided to stop this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-31
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Plan to share individual participant data: NO
Clinical trial NCT00251433: GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Official title: An Open-label, Multicenter, Phase I/II Dose Escalation Study of Oral GW572016 in Combination With Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-overexpressing Metastatic Breast Cancer
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: EGF100161 (NCT00251433) was terminated in Phase I (Phase II expansion portion of the study was never initiated) by sponsor decision.
Enrollment: 53.0 (ACTUAL)
Number of arms: 1.0
Start date: 2005-09-26
Primary completion date: 2010-06-10
Completion date: 2022-06-22
Plan to share individual participant data: NO
Clinical trial NCT01845805: Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Official title: A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-01-10
Primary completion date: 2021-04-09
Completion date: 2021-04-09
Clinical trial NCT04825223: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
Official title: Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision. Termination decision not related to any safety concern.
Enrollment: 576.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-03-29
Primary completion date: 2022-07-22
Completion date: 2022-07-22
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03995004: The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery
Official title: The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery
Sponsor: The University of Hong Kong (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Unable to secure study medication supply
Enrollment: 87.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2022-10-31
Primary completion date: 2024-09-30
Completion date: 2024-09-30
Plan to share individual participant data: NO
Clinical trial NCT02656849: BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Official title: A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Development of BAY1000394 has been terminated by Bayer.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-29
Primary completion date: 2019-10-31
Completion date: 2023-05-31
Clinical trial NCT05095480: Effect of Red Yeast Rice Beside Statin on Lipid Profile
Official title: Does Adding Red Yeast Rice to Statin Can Improve Lipid Profile or Vascular Inflammation? A Randomized Clinical Trial
Sponsor: Shiraz University of Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-01
Primary completion date: 2021-03-01
Completion date: 2021-04-01
Plan to share individual participant data: NO
IPD sharing description: only the result of study is available
Clinical trial NCT04394351: Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
Acronym: EoE KIDS
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 102.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-09-01
Primary completion date: 2022-06-02
Completion date: 2024-05-14
Baseline population: Analysis was performed on Part A full analysis set (FAS) which included all randomized participants in Part A.
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data that underlie publicly available results will be considered for sharing
IPD time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Clinical trial NCT03403634: Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Official title: Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients With Colorectal Cancer Metastatic to the Liver
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-19
Primary completion date: 2020-12-23
Completion date: 2021-08-29
Baseline population: There were 19 patients accrued to the study; however, 4 never received any treatment and became ineligible.
Clinical trial NCT04378075: A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Official title: Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Acronym: MIT-E
Sponsor: PTC Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision.
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-28
Primary completion date: 2023-03-18
Completion date: 2023-12-27
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02485899: An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Official title: A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Sponsor: BioMarin Pharmaceutical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-02-28
Primary completion date: 2020-12-10
Completion date: 2020-12-10
Baseline population: The demographic characteristics of the enrolled population are summarized for the 190-201/202 study (24 subjects). The demographic characteristics of the control group (NH comparator) which were necessary to determine the primary efficacy outcome measures, are also included (42 subjects).
Clinical trial NCT03751423: Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion
Official title: Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion
Sponsor: Queen's University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Study on-hold due to COVID-19 pandemic restrictions. Will resume when possible.
Enrollment: 123.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2019-06-10
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
Official title: A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician Choice Versus Treatment of Physician Choice for Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Systemic Chemotherapy Regimens for Advanced/Metastatic Setting
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor R \& D Strategy Adjustment\]
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-17
Primary completion date: 2022-01-17
Completion date: 2022-12-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03603964: Guadecitabine Extension Study
Official title: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Sponsor: Astex Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Early termination not due to patient safety
Enrollment: 35.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-18
Primary completion date: 2021-10-04
Completion date: 2021-10-04
Baseline population: Efficacy population included all participants who received any amount of study treatment.
Limitations and caveats: The study was terminated early not due to participant safety.
Plan to share individual participant data: NO
Clinical trial NCT03941093: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer
Official title: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Acronym: LAPIS
Sponsor: FibroGen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 284.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-10
Primary completion date: 2024-06-11
Completion date: 2024-06-11
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04965753: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Official title: A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Sponsor: Foghorn Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-17
Primary completion date: 2023-12-04
Completion date: 2023-12-04
Clinical trial NCT03756220: Ascorbic Acid and Thiamine Effect in Septic Shock
Official title: Combination Therapy of Vitamin C and Thiamine for Septic Shock: Multi-center, Double-blinded, Randomized, Controlled Study
Acronym: ATESS
Sponsor: Samsung Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 116.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-01
Primary completion date: 2020-01-13
Completion date: 2020-04-14
Plan to share individual participant data: NO
Clinical trial NCT04993352: Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
Official title: A Phase I/II, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of HLX04-O Administered by Intravitreal Injection in Subjects With Wet Age Related Macular Degeneration (wAMD)
Sponsor: Shanghai Henlius Biotech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-15
Primary completion date: 2022-07-07
Completion date: 2023-03-13
Plan to share individual participant data: NO
Clinical trial NCT04400799: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
Official title: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial
Sponsor: University of Zurich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: due to results from interim analysis
Enrollment: 475.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-15
Primary completion date: 2022-02-07
Completion date: 2022-04-12
Plan to share individual participant data: NO
Clinical trial NCT03326674: Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
Official title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Acronym: CONTESSA
Sponsor: Odonate Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Sponsor has discontinued the development of tesetaxel
Enrollment: 685.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-21
Primary completion date: 2020-08-24
Completion date: 2021-06-28
Plan to share individual participant data: UNDECIDED
IPD sharing description: Currently under evaluation by the organization
Clinical trial NCT04521335: Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Official title: A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Acronym: Repurpose-1
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Closed at PI's Request
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-21
Primary completion date: 2021-12-09
Completion date: 2022-02-06
Plan to share individual participant data: NO